The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The menopausal transition may represent an inflection point for worsening of multiple sclerosis in women, according to study findings.
People with multiple sclerosis (MS) face a significantly higher risk of perinatal mental illness compared to those with other ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
A new study reveals that people with multiple sclerosis (MS) experience significantly higher rates of mental illness during ...
Formerly believed to predominantly affect Caucasians, new research indicates that MS actually may hit Blacks the hardest.
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...
GlobalData on MSN4d
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis casesThe FDA reported that six patients died after being injected with Teva’s Copaxone or Sandoz’s Glatopa. The US Food and Drug ...
The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...
Earlier studies indicated that COVID infection might cause MS symptoms to worsen, particularly if the symptoms coincide with those associated with long COVID. For this new study, researchers tracked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback